Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-07-18FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory …
-
CLINICAL_TRIALS trial_result · 2022-07-06Clinical Trial Update: Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 trial evaluating safety and efficacy of deucravacitinib in moderate to severe ulcerative colitis has been completed with results pos…
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) [Phase 2, Phase 3]
A study evaluating safety and efficacy of upadacitinib for induction and maintenance therapy in moderately to severely active ulcerative col…
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis [Phase 2]
A Phase 2 trial evaluating SER-287 for adults with active ulcerative colitis was terminated; results posted in 2022.
-
FDA approval · 2022-06-17FDA Approved: ENTYVIO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ENTYVIO (vedolizumab) submitted by Takeda Pharmaceuticals America, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-03FDA Approved: MESALAMINE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for Mesalamine by Zydus Lifesciences Limited.
-
FDA approval · 2022-06-03FDA Approved: MESALAMINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for mesalamine filed by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Outcomes Mandate National Integration With Cannabis as Medicine [Phase 2]
Phase 2 clinical trial update focusing on integrating cannabis as medicine for various chronic pain conditions, with status currently UNKNOW…
-
CLINICAL_TRIALS trial_result · 2022-06-01Clinical Trial Update: Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis [Phase 4]
Phase 4 clinical trial evaluating a Novel Diet (UC DIET) for treatment of mild to moderate active pediatric ulcerative colitis has completed…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: Saffron and Ulcerative Colitis [Phase 2]
A Phase 2 clinical trial evaluating saffron for ulcerative colitis is underway, with unspecified status.
-
FDA approval · 2022-05-11FDA Approved: MESALAMINE — Original Application (Sun Pharmaceutical Industries Inc.)
The FDA approved the original ANDA application for mesalamine from Sun Pharmaceutical Industries Inc., granting generic drug approval. The a…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis [Phase 4]
Phase 4 trial comparing corticosteroids plus 5-aminosalicylic acid versus corticosteroids alone in moderate-severe ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis [Phase 2]
Phase 2 trial investigating safety, tolerability, efficacy, and dose-response of GSK2831781 in ulcerative colitis has terminated with posted…
-
CLINICAL_TRIALS trial_result · 2022-04-22Clinical Trial Update: Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial compares Budesonide Multimatrix (MMX) with Prednisolone for managing mild to moderate ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2022-04-22Clinical Trial Update: Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO) [Phase 2]
Phase 2 clinical trial update on probiotic treatment using Trichuris suis ova (TSO) for ulcerative colitis, completed.
-
CLINICAL_TRIALS trial_result · 2022-03-21Clinical Trial Update: Efficacy and Safety of BBT-401-1S in Ulcerative Colitis [Phase 2]
Phase 2 trial of BBT-401-1S in ulcerative colitis was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization [Phase 2]
Phase 2 trial updating golimumab in ulcerative colitis patients with loss of response followed by dose optimization has completed.
-
CLINICAL_TRIALS research · 2022-03-03Clinical Trial Update: Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
A completed clinical trial examining how infliximab drug levels correlate with outcomes in ulcerative colitis, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-02-28Clinical Trial Update: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) [Phase 3]
This Phase 3 induction study (LUCENT 1) evaluated mirikizumab in moderately to severely active ulcerative colitis; the trial has completed a…
-
CLINICAL_TRIALS trial_result · 2022-02-21Clinical Trial Update: To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
Clinical trial update for Remsima in Crohn's disease and ulcerative colitis; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis [Phase 3]
Phase 3 trial update on ontamalimab as maintenance therapy for moderate-to-severe ulcerative colitis; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients [Phase 2]
Phase 2 trial update on PBF-677 for ulcerative colitis reports safety and efficacy findings.
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission. [Phase 2]
Phase 2 trial of PF-06687234 as add-on to infliximab in active ulcerative colitis (not in remission) was terminated; results posted.
-
FDA approval · 2021-12-17FDA Approved: YUSIMRY — Original Application (Coherus BioSciences Inc)
FDA approved YUSIMRY (adalimumab-aqvh) from Coherus BioSciences in an original biologics license application, likely as a biosimilar to adal…
-
FDA approval · 2021-12-15FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application to introduce a 7-day starter pack of Zeposia (ozanimod hydrochloride) for Celgene Corporation.